FI962319A - C5a-reseptorin antagonistit, joilla ei ole olennaista agonistiaktiivisuutta - Google Patents

C5a-reseptorin antagonistit, joilla ei ole olennaista agonistiaktiivisuutta Download PDF

Info

Publication number
FI962319A
FI962319A FI962319A FI962319A FI962319A FI 962319 A FI962319 A FI 962319A FI 962319 A FI962319 A FI 962319A FI 962319 A FI962319 A FI 962319A FI 962319 A FI962319 A FI 962319A
Authority
FI
Finland
Prior art keywords
receptor antagonists
agonist activity
significant agonist
significant
activity
Prior art date
Application number
FI962319A
Other languages
English (en)
Swedish (sv)
Other versions
FI962319A0 (fi
Inventor
Oostrum Jan Van
William C Boyar
Nicholas G Galakatos
Jane V Peppard
Original Assignee
Ciba Geigy Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ciba Geigy Ag filed Critical Ciba Geigy Ag
Publication of FI962319A publication Critical patent/FI962319A/fi
Publication of FI962319A0 publication Critical patent/FI962319A0/fi

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/472—Complement proteins, e.g. anaphylatoxin, C3a, C5a
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Urology & Nephrology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Reproductive Health (AREA)
  • Psychiatry (AREA)
  • Transplantation (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Dermatology (AREA)
  • Vascular Medicine (AREA)
  • Endocrinology (AREA)
  • Pulmonology (AREA)
FI962319A 1993-12-06 1996-06-03 C5a-reseptorin antagonistit, joilla ei ole olennaista agonistiaktiivisuutta FI962319A0 (fi)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US16259193A 1993-12-06 1993-12-06
PCT/IB1994/000359 WO1995016033A1 (en) 1993-12-06 1994-11-16 C5a RECEPTOR ANTAGONISTS HAVING SUBSTANTIALLY NO AGONIST ACTIVITY

Publications (2)

Publication Number Publication Date
FI962319A true FI962319A (fi) 1996-06-03
FI962319A0 FI962319A0 (fi) 1996-06-03

Family

ID=22586301

Family Applications (1)

Application Number Title Priority Date Filing Date
FI962319A FI962319A0 (fi) 1993-12-06 1996-06-03 C5a-reseptorin antagonistit, joilla ei ole olennaista agonistiaktiivisuutta

Country Status (15)

Country Link
EP (1) EP0733107A1 (fi)
JP (1) JPH09506258A (fi)
CN (1) CN1142854A (fi)
AU (1) AU698919B2 (fi)
BR (1) BR9408265A (fi)
CA (1) CA2176825A1 (fi)
FI (1) FI962319A0 (fi)
HU (1) HUT75990A (fi)
IL (1) IL111792A0 (fi)
MX (1) MXPA99008669A (fi)
NO (1) NO962348L (fi)
NZ (1) NZ274917A (fi)
TW (1) TW429262B (fi)
WO (1) WO1995016033A1 (fi)
ZA (1) ZA949647B (fi)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5837499A (en) * 1993-12-06 1998-11-17 Ciba-Geigy Corporation DNA encoding C5A receptor antagonists having substantially no agonist activity and methods of expressing same
JPH11507215A (ja) * 1995-06-05 1999-06-29 ノバルティス・アクチエンゲゼルシャフト アゴニスト活性を実質的にもたないＣ５ａ受容体アンタゴニストおよび製造方法
CN1087572C (zh) * 1995-12-13 2002-07-10 北方电讯网络有限公司 集成蜂窝话音和数字分组数据电信系统及该系统的运行方法
AUPO755097A0 (en) * 1997-06-25 1997-07-17 University Of Queensland, The Receptor agonist and antagonist
TWI767415B (zh) * 2020-11-18 2022-06-11 中國醫藥大學 自動化血液分析系統及自動化血液分析方法
CN113150106B (zh) * 2021-04-26 2022-08-16 华中农业大学 来源于补体成分C5a的抗菌肽及其应用

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0305615A1 (en) * 1987-09-03 1989-03-08 Immunetech Pharmaceuticals, Inc. Peptide antagonists for the C5a anaphylatoxin
EP0245993B1 (en) * 1986-04-28 1993-05-26 Cetus Oncology Corporation Monoclonal antibodies against c5a and des-arg74-c5a, their production and use

Also Published As

Publication number Publication date
JPH09506258A (ja) 1997-06-24
HUT75990A (en) 1997-05-28
CN1142854A (zh) 1997-02-12
NO962348D0 (no) 1996-06-05
FI962319A0 (fi) 1996-06-03
TW429262B (en) 2001-04-11
HU9601538D0 (en) 1996-07-29
BR9408265A (pt) 1996-12-10
CA2176825A1 (en) 1995-06-15
ZA949647B (en) 1995-06-06
AU8002594A (en) 1995-06-27
NO962348L (no) 1996-08-05
EP0733107A1 (en) 1996-09-25
IL111792A0 (en) 1995-01-24
NZ274917A (en) 1998-03-25
WO1995016033A1 (en) 1995-06-15
MXPA99008669A (es) 2004-09-01
AU698919B2 (en) 1998-11-12

Similar Documents

Publication Publication Date Title
NO965608D0 (no) Vitronectin-reseptor-antagonister
NO983001D0 (no) Vitronectin-reseptor-antagonister
NO983003D0 (no) Vitronectin-reseptor-antagonister
DK0957917T3 (da) Vitronectinreceptorantagonister
NO983002D0 (no) Vitronectin-reseptor-antagonister
NO972016D0 (no) Indolyl-Y-reseptorantagonister
ZA955391B (en) Vitronectin receptor antagonists
NO993350D0 (no) Vitronectin-reseptor-antagonister
NO950606D0 (no) Adhesjonsreseptor-antagonister
ID24726A (id) Antagonis-antagonis reseptor trombin
NO20001514D0 (no) Vitronectin-reseptor-antagonist
NO20001407D0 (no) Vitronectin-reseptor-antagonister
NO20001515D0 (no) Vitronektin reseptor-antagonist
DK0906294T3 (da) Benzoxazinon-dopamin D4-receptor-antagonister
DZ2322A1 (fr) Antagonistes de récepteurs de vitronectine.
FI962319A (fi) C5a-reseptorin antagonistit, joilla ei ole olennaista agonistiaktiivisuutta
NO179550C (no) Tachykinin reseptorantagonister
DE59503324D1 (de) Adhäsionsrezeptor-Antagonisten
DK0660832T3 (da) Serotoninreceptor-midler
SI0957917T1 (sl) Antagonisti receptorja vitronektina

Legal Events

Date Code Title Description
GB Transfer or assigment of application

Owner name: NOVARTIS AG